Business & Regulation

The EMA says it will review its standards for first-in-human trials

A survey-based report highlights wildly inaccurate drug demand projections

Astronomers Chris Leigh and Mike Merrifield debate how a potential Brexit might impact UK science

Steve Bates, CEO of the British BioIndustry Association (BIA) explains why he thinks the UK bioindustry is stronger inside the European Union.

As politicians and the public argue over the minor point of the UK leaving Europe, we ask a more important question: what will a “Brexit” mean for the global pharmaceutical industry?

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?

Abbott, Abbvie and Sanofi all make separate merger announcements – on the same day

What’s the best way to present a health resource? Apparently, ease of use trumps all other factors

Are you a budding biotech or pharma startup? “The Hive” could be your chance to showcase your work